中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.012 seconds)

    Pharmaceutical Combinations
    2.
    发明申请
    Pharmaceutical Combinations 审中-公开
    药物组合

    公开(公告)号：US20160339023A1

    公开(公告)日：2016-11-24

    申请号：US15107232

    申请日：2014-12-19

    Applicant: Fang Li ,  Hui-Qin WANG ,  Ensar HALILOVIC ,  Jinsheng LIANG

    Inventor： Fang Li ,  Hui-Qin WANG ,  Ensar HALILOVIC ,  Jinsheng LIANG

    IPC: A61K31/506 ,  A61K31/496

    CPC classification number: A61K31/506 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/435 ,  A61K31/496 ,  A61K45/06 ,  A61K2300/00

    Abstract: A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

    Abstract translation: 一种药物组合，其包含（a）ALK抑制剂或其药学上可接受的盐，和（b）至少一种HDMA-2 / p53受体抑制剂或其药学上可接受的盐，或至少一种BRaf抑制剂或药学上可接受的盐， 和任选的药学上可接受的载体，用于同时，分别或连续施用; 这种组合在治疗癌症中的用途; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

    PHARMACEUTICAL COMPOSITIONS
    3.
    发明申请
    PHARMACEUTICAL COMPOSITIONS 审中-公开
    药物组合物

    公开(公告)号：US20160331751A1

    公开(公告)日：2016-11-17

    申请号：US15106886

    申请日：2014-12-19

    Applicant: Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    Inventor： Stephane Ferretti ,  Sebastien Jeay ,  Ensar Halilovic ,  Fang Li ,  Hui-Qin Wang

    IPC: A61K31/519 ,  A61K31/506 ,  A61K31/496

    CPC classification number: A61K31/519 ,  A61K31/4188 ,  A61K31/496 ,  A61K31/505 ,  A61K31/506 ,  A61K2300/00

    Abstract: The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

    Abstract translation: 本公开涉及mdm2 / 4抑制剂的药物组合，即（S）-1-（4-氯 - 苯基）-7-异丙氧基-6-甲氧基-2-（4- {甲基 - [4-（4 - 甲基-3-氧代 - 哌嗪-1-基） - 反式 - 环己基甲基] - 氨基} - 苯基）-1,4-二氢-2H-异喹啉-3-酮或（S）-5-（5-氯 - -1-甲基-2-氧代-1,2-二氢 - 吡啶-3-基）-6-（4-氯 - 苯基）-2-（2,4-二甲氧基 - 嘧啶-5-基）-1-异丙基 -5,6-二氢-1H-吡咯并[3,4-d]咪唑-4-酮和细胞周期蛋白依赖性激酶4/6（CDK4 / 6）抑制剂7-环戊基-2-（5-哌嗪-1-基） 吡啶-2-基氨基）-7H-吡咯并[2,3-d]嘧啶-6-甲酸二甲基酰胺。 此外，本公开涉及药物组合产品。 本公开还涉及包含所述mdm2 / 4抑制剂或细胞周期蛋白依赖性激酶4/6（CDK4 / 6）抑制剂的相应药物制剂，用途和治疗方法。

    Combination of PI3K Inhibitor and C-Met Inhibitor
    4.
    发明申请
    Combination of PI3K Inhibitor and C-Met Inhibitor 审中-公开
    PI3K抑制剂和C-Met抑制剂的组合

    公开(公告)号：US20150216870A1

    公开(公告)日：2015-08-06

    申请号：US14420792

    申请日：2013-08-14

    Applicant: Giordano Caponigro ,  Xizhong Huang ,  Joseph Lehar ,  Hui-Qin Wang

    Inventor： Giordano Caponigro ,  Xizhong Huang ,  Joseph Lehar ,  Hui-Qin Wang

    IPC: A61K31/53 ,  A61K31/5377 ,  A61K31/4439 ,  A61K31/4745

    CPC classification number: A61K31/53 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

    Abstract: The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.

    Abstract translation: 本发明涉及药物组合，其包含（a）磷脂酰肌醇3-激酶抑制剂或其药学上可接受的盐，和（b）至少一种c-Met受体酪氨酸激酶抑制剂或其药学上可接受的盐，用于同时，分开或 顺序给药用于治疗增殖性疾病，特别是c-Met依赖性增殖性疾病; 包含这种组合的药物组合物; 治疗具有增殖性疾病的受试者的方法，包括向有需要的受试者施用所述组合; 使用这种组合治疗增生性疾病; 以及包括这种组合的商业包装。

Patent Agency Ranking